Our CEO Roman Grunt was very proud to be a guest speaker at the First International Forum on Innovation and Research of Drugs for Cancer event, and share how QUINTA-ANALYTICA manages it’s clinical trials. We were excited and pleased to accompany so many internationally renowned experts from academia and industry, including the fantastic other guest speakers to discuss the latest progress in cancer research. Thank you Atengen, Inc. for inviting us to join you in Tianjin, China!

Additional News

  • 25 March 2026

    ADC Webinar: DAR, Bioanalysis and Intact MS in Next-Generation ADC Development

    On behalf of Conscio Group, registration is now open for our free expert-led webinar on DAR characterization, bioanalytical strategy and mass spectrometry insight in ADC development.

  • 17 December 2025

    PF 2026: Thank You from Quinta-Analytica

    In 2025, Quinta-Analytica continued to turn complex development challenges into tangible progress. Our PF 2026 message looks back at key milestones and thanks the partners, clients, and teams who made them possible.

  • 15 December 2025

    IVBE for locally acting drugs: insights from Conscio Science Day in Munich

    Can bioequivalence for locally acting drugs be demonstrated without a single subject in a clinical trial? Yes, if your in vitro bioequivalence (IVBE) toolkit is set up in the right way.

ALL POSTS